Needham & Company analyst Gil Blum reiterated a Buy rating and $32.00 price target on Taysha Gene Therapies (NASDAQ: TSHA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE